Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage.

Abdel Meguid MH, Hamad YH, Swilam RS, Barakat MS.

Rheumatol Int. 2013 Mar;33(3):697-703. doi: 10.1007/s00296-012-2375-7. Epub 2012 Apr 25.

PMID:
22531887
2.

Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis.

Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y.

Joint Bone Spine. 2010 May;77(3):201-5. doi: 10.1016/j.jbspin.2010.03.002. Epub 2010 May 4. Review.

PMID:
20444632
3.

Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis.

Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L.

Cytokine. 2012 Apr;58(1):6-9. doi: 10.1016/j.cyto.2011.12.010. Epub 2012 Jan 10.

PMID:
22239947
4.

Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.

Bøyesen P, Hoff M, Odegård S, Haugeberg G, Syversen SW, Gaarder PI, Okkenhaug C, Kvien TK.

Arthritis Res Ther. 2009;11(4):R103. doi: 10.1186/ar2749. Epub 2009 Jul 1.

5.
6.

[Osteoporosis in rheumatoid arthritis--significance of alfacalcidol in prevention and therapy].

Schacht E.

Z Rheumatol. 2000;59 Suppl 1:10-20. Review. German.

PMID:
10769429
7.

Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy.

Cortet B, Flipo RM, Blanckaert F, Duquesnoy B, Marchandise X, Delcambre B.

Rev Rhum Engl Ed. 1997 Jul-Sep;64(7-9):451-8.

PMID:
9338926
8.

Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis.

Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S.

J Rheumatol. 2003 Mar;30(3):474-9.

PMID:
12610804
9.

Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis.

Wisłowska M, Jakubicz D, Stepień K, Cicha M.

Rheumatol Int. 2009 Oct;29(12):1403-9. doi: 10.1007/s00296-009-0867-x. Epub 2009 Feb 15.

PMID:
19219607
10.

Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?

Korczowska I, Olewicz-Gawlik A, Trefler J, Hrycaj P, Krzysztof Łacki J.

Clin Rheumatol. 2008 May;27(5):565-72. Epub 2007 Oct 2.

PMID:
17909741
11.

Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.

Lange U, Teichmann J, Müller-Ladner U, Strunk J.

Rheumatology (Oxford). 2005 Dec;44(12):1546-8. Epub 2005 Nov 1.

PMID:
16263785
12.

Interleukin-1 gene polymorphism disease activity and bone mineral metabolism in rheumatoid arthritis.

Zhang X, Llamado L, Pillay I, Price P, Will R.

Chin Med J (Engl). 2002 Jan;115(1):46-9.

PMID:
11930657
14.

Plasma level of neopterin as a marker of disease activity in treated rheumatoid arthritis patients: association with gender, disease activity and anti-CCP antibody.

Arshadi D, Nikbin B, Shakiba Y, Kiani A, Jamshidi AR, Boroushaki MT.

Int Immunopharmacol. 2013 Nov;17(3):763-7. doi: 10.1016/j.intimp.2013.08.022. Epub 2013 Sep 18.

PMID:
24055018
15.

Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density.

Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE, Hazes JM, Dijkmans BA, Lems WF.

Ann Rheum Dis. 2004 Dec;63(12):1576-80.

16.

IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients.

Roşu A, Mărgăritescu C, Stepan A, Muşetescu A, Ene M.

Rom J Morphol Embryol. 2012;53(1):73-80.

17.

Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis.

Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P.

J Rheumatol. 1998 Jul;25(7):1282-9.

PMID:
9676757
18.

Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.

Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M.

Ann N Y Acad Sci. 2006 Jun;1069:420-7.

PMID:
16855169
19.

Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.

Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.

Arthritis Res. 1999;1(1):81-91. Epub 1999 Oct 26.

20.

Are anti-citrulline autoantibodies better serum markers for rheumatoid arthritis than rheumatoid factor in Thai population?

Vanichapuntu M, Phuekfon P, Suwannalai P, Verasertniyom O, Nantiruj K, Janwityanujit S.

Rheumatol Int. 2010 Apr;30(6):755-9. doi: 10.1007/s00296-009-1058-5. Epub 2009 Jul 12.

PMID:
19597732

Supplemental Content

Support Center